Teva Gains U.S. Approval for Higher-Dose Copaxone Therapy
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. gained U.S. approval for a longer-acting version of the Copaxone multiple-sclerosis drug, bolstering the company’s effort to defend its best-selling product as competitors seek to introduce cheaper copies this year.
Teva can now market Copaxone for use as a 40-milligram shot three times a week, the Petach Tikva, Israel-based company said yesterday in a statement. Teva sells a 20-milligram daily injection, which last year generated $4.2 billion in sales, based on analysts’ estimates compiled by Bloomberg.